We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

InvestoGain Australia

Celebrating 20 Years in Business

Thank you for being part of our development since September 2001. With your ongoing support we look forward to many exciting developments ahead.


Any AUS or NZ company


Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

VIRAX HOLDINGS LIMITED24/03/199715/12/2014

Shareholder links

Our website ranking of PTX: rating 4
(4 out of 5)



Automic Registry Services Level 5, 126 Phillip Street Sydney NSW 2000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PTX3
Address: Level 4, 100 Albert Road South Melbourne Victoria, 3205
Tel:  +61 (0) 3 9692 7222 Fax: +61 (0) 3 9077 9233

Date first listed: 19/12/1986
Company Secretary: Ms Melanie Leydin
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Bio-pharmaceutical research and development investment

News & Events

Expand this box to read and print

The suspension of trading in the securities of Prescient Therapeutics Limited will be lifted from the commencement of trading on Tuesday, 26 May 2020, following the release by PTX of an announcement regarding a material licence agreement.


PTX obtains global, exclusive licence from University of Pennsylvania for an innovative universal immune receptor platform for the development of innovative cell therapies. PTX also has a global, non-exclusive licence from Oxford University to use the novel molecular binding system that is complementary with the Penn technology. PTX plans to incorporate the technologies from Penn, Oxford University and other assets, to build a universal chimeric immune receptor platform termed OmniCAR for next generation cell therapy product development. OmniCAR will enable in-house development of next generation engineered cell therapies and create opportunities for collaboration and business development in the cell therapy field for PTX. PTX's long term goal is to harness OmniCAR's innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products.


The securities of Prescient Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PTX, pending the release of an announcement regarding a material licence agreement.


name changed from Virax Holdings Limited


we understand that on or about this date the company consolidated its shares 1 for 20

OFX Transferring Money Internationally to Free


Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

I have a Transaction Confirmation Statement indicating my shares have been consolidated on a 1 to 10 basis, with a closing balance of 8400.  Can I sell this so any loss made can be registered in my name for tax purposes?

16/09/2019 17:10:46

consolidation of shares leaves me with only 156 shares of PTX


Do you purchase small parcels for a fee so I can  use the loss for tax purposes?

11/04/2017 16:04:17

Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    26/03/2019James Campbell178,125$0.056$9,968
    08/11/2016Paul Hopper50,000$0.100$5,000
    26/07/2016Paul Hopper40,000$0.110$4,400
    07/12/2015Paul Hopper50,000$0.093$4,650

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Steven EngleNon Exec Chairman28/11/2014
    Steven Yatomi-ClarkeManaging Director, CEO28/11/2014
    Allen EbensNon Exec Director01/06/2020
    James CampbellNon Exec Director28/11/2014

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Paul HopperNon Exec Director02/06/201402/01/2020
    Rob CrombieManaging Director18/06/201415/10/2015
    Wayne MillenExecutive Chairman02/09/201328/11/2014
    Roland ToderNon Exec Director02/09/201328/11/2014
    Brendan de KauweNon Exec Director02/09/201328/11/2014
    Michael HumphrisChairman, Non Exec Director16/01/200802/09/2013
    Ian PymanNon Exec Director16/01/200802/09/2013
    John MorrisonDirector13/03/201202/09/2013
    Larry WardCEO20/12/200724/08/2012
    Albert KingNon Exec Director16/01/200812/02/2011

    Date of first appointment, title may have changed.